



January 9, 2017

The BSE Limited
Stock Exchange Towers,
Dalal Street, Fort,
Mumbai- 400 023

GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurgaon (Haryana), India - 122002

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

Dear Sir/Madam,

Sub: Statement of Investor Complaints under Regulation 13 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we would like to submit the Statement stating the number of Investor Complaints received and disposed of during the quarter ended December 31, 2016

The details are as follows:

Description	Opening Balance as on 01/10/2016	Received during the Period 01/10/2016 to 31/12/2016	Attended/Resolved during the Period 01/10/2016 to 31/12/2016	Pending as on 31/12/2016
Non-receipt of Dividend	NIL	30	30	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of share certificates	NIL	02	02	NIL
SEBI	NIL	01	01	NIL
Stock Exchange	NIL	Nil	Nil	Nil
Total	NIL	33	33	NIL

You are requested to take the above information on your records.

Thanking you.

Yours faithfully,
For GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary